Covered recipient · General Payments record
VISHALA CHINDALORE
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$5,174.55
208 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,140.97 | 205 |
| Consulting Fee | $2,000.00 | 1 |
| Education | $33.58 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $2,226.86 | 15 |
| AbbVie Inc. | $596.58 | 30 |
| Amgen Inc. | $405.92 | 30 |
| UCB, Inc. | $404.81 | 29 |
| PFIZER INC. | $325.42 | 23 |
| GlaxoSmithKline, LLC. | $188.56 | 11 |
| Lilly USA, LLC | $157.42 | 10 |
| Novartis Pharmaceuticals Corporation | $151.72 | 10 |
| E.R. Squibb & Sons, L.L.C. | $147.63 | 9 |
| Rigel Pharmaceuticals, Inc. | $124.85 | 1 |
| Horizon Therapeutics plc | $116.90 | 22 |
| Mallinckrodt Hospital Products Inc. | $70.31 | 4 |
| Aurinia Pharma U.S., Inc. | $56.60 | 2 |
| AstraZeneca Pharmaceuticals LP | $56.44 | 3 |
| Radius Health, Inc. | $45.05 | 3 |
| Ultragenyx Pharmaceutical Inc. | $24.08 | 1 |
| Sobi, Inc | $17.35 | 1 |
| PBG PUERTO RICO LLC | $17.08 | 1 |
| Eisai Inc. | $15.58 | 1 |
| DePuy Synthes Sales Inc. | $12.90 | 1 |
| Cumberland Pharmaceuticals, Inc. | $12.49 | 1 |
Page 4 of 5; records 151–200 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
VISHALA CHINDALORE
NPI 1083635015 · CMS profile ID 94470
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
ANNISTON, AL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 5; records 151–200 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1083635015?year=2021&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- VISHALA CHINDALORE, NPI 1083635015, CMS profile ID 94470. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083635015?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). VISHALA CHINDALORE, NPI 1083635015, CMS profile ID 94470. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083635015?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- VISHALA CHINDALORE, NPI 1083635015, CMS profile ID 94470, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1083635015?year=2021&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
208 matching records · $5,174.55 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 208.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $13.15 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802380735 | CMS |
| Horizon Therapeutics plc | $3.34 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797096551 | CMS |
| Lilly USA, LLC | $18.98 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818781199 | CMS |
| AbbVie Inc. | $20.44 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794251219 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.97 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783618781 | CMS |
| Janssen Biotech, Inc. | $18.45 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787671811 | CMS |
| Amgen Inc. | $19.56 | 04/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825860789 | CMS |
| Horizon Therapeutics plc | $4.72 | 04/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797096545 | CMS |
| PFIZER INC. | $15.75 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832724977 | CMS |
| Horizon Therapeutics plc | $7.32 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797096541 | CMS |
| Novartis Pharmaceuticals Corporation | $15.26 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812636331 | CMS |
| AbbVie Inc. | $24.25 | 03/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794251217 | CMS |
| Amgen Inc. | $18.28 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825860821 | CMS |
| UCB, Inc. | $13.34 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807316049 | CMS |
| Lilly USA, LLC | $18.72 | 03/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818767155 | CMS |
| GlaxoSmithKline, LLC. | $13.15 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802059239 | CMS |
| PFIZER INC. | $15.04 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832708863 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.83 | 03/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783618773 | CMS |
| Janssen Biotech, Inc. | $15.74 | 03/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787671762 | CMS |
| Amgen Inc. | $5.27 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825860785 | CMS |
| Novartis Pharmaceuticals Corporation | $15.37 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812636329 | CMS |
| AbbVie Inc. | $20.83 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794251215 | CMS |
| Eisai Inc. | $15.58 | 03/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 817869059 | CMS |
| PFIZER INC. | $15.04 | 03/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832641543 | CMS |
| Amgen Inc. | $17.74 | 03/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825860781 | CMS |
| Horizon Therapeutics plc | $7.73 | 02/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797096537 | CMS |
| PFIZER INC. | $10.43 | 02/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832724291 | CMS |
| Janssen Biotech, Inc. | $16.17 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787671733 | CMS |
| Mallinckrodt Hospital Products Inc. | $16.43 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845350621 | CMS |
| UCB, Inc. | $12.57 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807303525 | CMS |
| Amgen Inc. | $20.43 | 02/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825860817 | CMS |
| Horizon Therapeutics plc | $5.23 | 02/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797096533 | CMS |
| Lilly USA, LLC | $18.98 | 02/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818813271 | CMS |
| GlaxoSmithKline, LLC. | $13.15 | 02/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802325386 | CMS |
| Horizon Therapeutics plc | $2.22 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797096529 | CMS |
| PBG PUERTO RICO LLC | $17.08 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832654517 | CMS |
| Janssen Biotech, Inc. | $18.92 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787671803 | CMS |
| AbbVie Inc. | $22.71 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794251213 | CMS |
| UCB, Inc. | $18.92 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807317405 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.73 | 02/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783618763 | CMS |
| PFIZER INC. | $13.27 | 02/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832678481 | CMS |
| Horizon Therapeutics plc | $4.63 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797096525 | CMS |
| Janssen Biotech, Inc. | $14.81 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787671791 | CMS |
| Amgen Inc. | $14.71 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826452855 | CMS |
| AbbVie Inc. | $21.43 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794251211 | CMS |
| Lilly USA, LLC | $18.98 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818813269 | CMS |
| UCB, Inc. | $11.78 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807296623 | CMS |
| PFIZER INC. | $14.10 | 01/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832566769 | CMS |
| GlaxoSmithKline, LLC. | $16.02 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802506809 | CMS |
| Novartis Pharmaceuticals Corporation | $15.40 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812636327 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $766.64 | 1 |
| PY2025 | Principal investigator | $588,347.88 | 49 |
| PY2024 | Principal investigator | $464,278.86 | 112 |
| PY2023 | Recipient | $3,200.00 | 1 |
| PY2023 | Principal investigator | $387,183.21 | 106 |
| PY2022 | Recipient | $24,632.48 | 2 |
| PY2022 | Principal investigator | $596,933.64 | 42 |
| PY2021 | Principal investigator | $189,276.51 | 71 |
| PY2020 | Recipient | $300.00 | 1 |
| PY2020 | Principal investigator | $496,910.27 | 53 |
| PY2019 | Recipient | $6,865.46 | 1 |
| PY2019 | Principal investigator | $728,546.57 | 59 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
50 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Daiichi Sankyo Company LTD | $3,314.00 | 11/07/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1186252419 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $260.00 | 11/07/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376205 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $526.00 | 11/07/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376219 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,278.00 | 11/07/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376227 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,250.00 | 11/07/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376233 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,064.30 | 11/05/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120719 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,109.71 | 10/31/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL | No dispute reported | 06/30/2026 | 1190306177 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10,600.00 | 10/15/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | An Open label Phase I Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AZD5492 Following Single ascending Dose and Step up Dose Administration to Adult Participants with Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies | No dispute reported | 06/30/2026 | 1185545051 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $479.00 | 10/14/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | PhI SAD study of MOSUN in patients with SLE | No dispute reported | 06/30/2026 | 1211638629 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $546.00 | 10/14/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | PhI SAD study of MOSUN in patients with SLE | No dispute reported | 06/30/2026 | 1211638633 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $10,343.15 | 10/14/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | PhI SAD study of MOSUN in patients with SLE | No dispute reported | 06/30/2026 | 1211638638 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,709.00 | 10/14/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | PhI SAD study of MOSUN in patients with SLE | No dispute reported | 06/30/2026 | 1211638643 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,097.90 | 10/02/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120230 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.31 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376195 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.86 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376197 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.36 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376199 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.93 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376201 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.34 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376203 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.86 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376207 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.24 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376209 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2.04 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376211 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2.04 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376213 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2.04 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376215 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.24 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376217 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.70 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376221 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.68 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376223 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2.04 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376225 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.62 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376229 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.36 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376231 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.86 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376235 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.55 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376237 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.02 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376239 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1.86 | 10/01/2025 | Non-covered Recipient Entity Pinnacle Research Group LLC | DS7011-107 | No dispute reported | 06/30/2026 | 1223376241 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,050.90 | 09/03/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120217 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $38,996.00 | 08/21/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | PhI SAD study of MOSUN in patients with SLE | No dispute reported | 06/30/2026 | 1211638612 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,403.90 | 08/01/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120249 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,318.30 | 07/02/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120726 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $6,925.00 | 06/12/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | PhI SAD study of MOSUN in patients with SLE | No dispute reported | 06/30/2026 | 1211638608 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,314.40 | 06/04/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120236 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,608.00 | 05/09/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120241 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,049.20 | 04/02/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120713 |
| Recipient | F. Hoffmann-La Roche AG | $766.64 | 03/31/2025 | Covered Recipient Physician | PhI SAD study of MOSUN in patients with SLE | No dispute reported | 06/30/2026 | 1211539477 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $2,551.62 | 03/25/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lupus Erythematosus | No dispute reported | 06/30/2026 | 1214125424 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $20,293.20 | 03/07/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120212 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,382.50 | 02/05/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120223 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $62,476.00 | 01/28/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) | No dispute reported | 06/30/2026 | 1190299306 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $191,443.43 | 01/27/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | No dispute reported | 06/30/2026 | 1190299310 |
| Principal investigator 1 | ABBVIE INC. | $510.00 | 01/14/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202438216 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $117,915.32 | 01/09/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP LLC | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190299301 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,505.10 | 01/08/2025 | Non-covered Recipient Entity PINNACLE RESEARCH GROUP | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192120708 |